Brooke E. Wilson

Dr. Brooke E. Wilson


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2019 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
BWBrooke E. Wilson
Brooke E. Wilson
BRBertrand Routy
Bertrand Routy
ANAdnan Nagrial
Adnan Nagrial
VCVenessa T. Chin
Venessa T. Chin

11 November 2024 in eClinicalMedicine
Verified
Journal Article
Open access
BWBrooke E. Wilson
Brooke E. Wilson
CBChristopher M. Booth
Christopher M. Booth
Real-world data (RWD) are rapidly emerging sources of information for patients, clinicians and regulators. While randomized controlled trials (RCTs) reduce bias and confounding through the randomization process and provide the highest quality of evidence regarding drug efficacy, RCTs may be impractical or unfeasible for rare diseases or disease subsets. And yet, studies attempting to replicate clinical trial results using observational datasets have failed. Given the inherent differences between observational data and clinical trial results, this discordance is not surprising. However, RWD may still have independent value as complementary tools to trial results. In this viewpoint, we explore the challenges of RWD and discuss key questions that clinicians, patients, and regulators will need to consider when faced with positive efficacy data from clinical trials, and negative effectiveness data from real world studies. Finally, we explore novel trial designs that might help bridge the gap from RCTs to RWD.

11 May 2022 in European Journal of Cancer
Verified
Journal Article
Open access
BWBrooke E. Wilson
Brooke E. Wilson
AAAndrew J Armstrong
Andrew J Armstrong
JBJohann de Bono
Johann de Bono
CSCora N. Sternberg
Cora N. Sternberg
CRCharles J. Ryan
Charles J. Ryan
AJAnthony Joshua
Anthony Joshua
The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48–0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47–0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62–0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62–0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68–0.88). Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP.

5 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SNSabrina Nucera
Sabrina Nucera
CCChiara Conti
Chiara Conti
FMFederica Martorana
Federica Martorana
BWBrooke E. Wilson
Brooke E. Wilson
Sofia GentaSofia Genta
Sofia Genta
Antibody-drug conjugates (ADCs) represent an effective class of agents for the treatment of several tumor types, including breast cancer (BC), featuring approved molecules such as trastuzumab-emtansine, trastuzumab-deruxtecan, and sacituzumab-govitecan. Immune-checkpoint inhibitors (ICIs) also showed activity in selected BC subtypes, and two agents, pembrolizumab and atezolizumab, are currently approved for the treatment of triple-negative BC patients. The potential synergy between ADCs and immunotherapy in BC remains an area of active investigation. Preclinical studies suggest that ADCs promote immune surveillance, modulating tumor microenvironment, inducing immunogenic cell death, and enhancing antitumor immunity. Translational evidence has shown potential predictive biomarkers for ADCs alone or in combination with immunotherapy, including expression of target antigen, oncogenic pathways, tumor-infiltrating lymphocytes, and neutrophil-to-lymphocyte ratio. Given this background, several clinical trials evaluated ADC-ICI combinations in BC patients, demonstrating promising outcomes with an overall manageable toxicity profile, and many studies are currently ongoing to confirm the efficacy and feasibility of this therapeutic approach. In the present review, we summarized the available evidence about the integration of ADCs and immunotherapy for the management of BC, emphasizing the need for further translational and clinical investigations to optimize this treatment strategy and elucidate predictive biomarkers, eventually improving patient outcomes.

1 July 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BWBrooke E. Wilson
Brooke E. Wilson
KWKristin Wright
Kristin Wright
RKRachel Koven
Rachel Koven
CBChristopher Booth
Christopher Booth

2 November 2023 in Cancer
Verified
Journal Article
Open access
BWBrooke E. Wilson
Brooke E. Wilson
THTimothy P. Hanna
Timothy P. Hanna
CBChristopher Booth
Christopher Booth
The efficacy‐effectiveness (EE) gap describes the differences in survival seen in clinical trials and routine clinical practice, where patients in real‐world practice often have inferior outcomes compared to trial populations. However, EE gaps may exist beyond survival outcomes, including gaps in quality of life, toxicity, cost‐effectiveness, and patient time, and these EE gaps should also influence patient and clinician treatment decisions. Failure to clearly acknowledge these EE gaps may cause patients, clinicians, and health care systems to have unrealistic expectations of the benefits of therapy across a range of important clinical and economic domains. In this commentary, the authors review the evidence supporting the existence of EE gaps in quality of life, time toxicity, cost and toxicities, and urge for further research into this important topic.